Tevogen Registers 1.03M Lender Shares for Resale as Cash Falls to $144,713
TVGN sits 60% above its 52-week low of $3.636 on light trading volume (0.4× avg).
Summary
Tevogen registered 1,029,126 shares for resale by lender The Patel Family, LLP — shares issued as loan principal and interest payments, not a new capital raise. The company receives no proceeds while its cash position stood at $144,713 at the last quarterly report.
Key Events · Financing and Capital Events · TVGN
-
Lender Shares Registered for Resale
Up to 1,029,126 shares held by The Patel Family, LLP may be sold from time to time, consisting of 1,000,000 principal shares and 29,126 interest shares issued in November 2026 under the amended loan agreement.
-
No Proceeds to the Company
Tevogen sells no shares and receives no proceeds; it bears roughly $46,504 of registration costs (including a $504.08 SEC fee) while the lender keeps all sale proceeds.
-
Debt Paid in Stock, Not Cash
Principal and interest share payments are priced at $7.40 per share, above the $6.00 closing price on November 13, 2026, and the registration fee table values the shares at $5.63 each for a $5.79 million aggregate.
-
Sale Restrictions Limit the Overhang
For one year from issuance the lender cannot sell more than 10% of three-week average daily volume per day, cannot lend the shares, and cannot short or hedge the stock while the credit line is outstanding; a 9.99% ownership blocker applies.
Analysis · TVGN · Life Sciences
Tevogen is putting 1,029,126 shares on the market for The Patel Family, LLP — the related party that holds its credit line — as payment of loan principal and interest rather than cash. The company gets nothing from these sales; the lender does. That matters because the 10-Q filed one day earlier showed only $144,713 of cash and missed payroll in October and November, so every share-based debt payment is a sign the company is conserving cash it does not have. The shares equal roughly 1.5% of the 68,678,743 shares outstanding, and the lender is barred from selling more than 10% of three-week average daily volume per day in the first year, which limits but does not remove the overhang on a thinly traded stock.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVGN was trading at $5.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.5M. The 52-week trading range was $3.64 to $24.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.